1. Kummar Shivaani
2. Doroshow James H

9789350252727

10.5005/jp/books/11216_4

1/e

2011

12

1. Medical Oncology Branch, National Cancer Institute, 9000 Rockville Pike Building 10, Room 13N240G, Bethesda, MD 20892
2. Medical Oncology Branch, National Cancer Institute, 9000 Rockville Pike, Building 10, Room 13N240G, Bethesda, MD 20892

Phase I clinical trials, Phase 0 Trials, investigational New drug, pharmacodynamic (PD) endpoints, Primary endpoint, PK/ PD analysis, PD assay, standard operating procedures, PD assay validation, IND-enabling studies, new drug evaluations, PARP activity, ABT-888, FDA approval rates, oncology, microdosing, pharmacokinetics, pharmacodynamics, toxicology studies, ADP-ribose, DNA repair enzyme, xenograft models, PARP inhibition, matrix metalloproteinase inhibitors